Heart failure drug gets extended safety check in 800 patients
NCT ID NCT07436689
Summary
This study provides continued access to an experimental oral medication called levosimendan (TNX-103) for people with pulmonary hypertension linked to a specific type of heart failure. It aims to monitor the long-term safety of the drug in 800 participants who have already taken it in previous trials. The main goal is to track side effects and serious adverse events over extended use.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION ASSOCIATED WITH HFPEF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tenax Investigational Site
Chicago, Illinois, 60611, United States
-
Tenax Investigational Site
Minneapolis, Minnesota, 55455, United States
-
Tenax Investigational Site
Rochester, Minnesota, 55905, United States
-
Tenax Investigational Site
St Louis, Missouri, 63136, United States
-
Tenax Investigational Site
Charleston, South Carolina, 29425, United States
Conditions
Explore the condition pages connected to this study.